Cardiovascular Medicine and Haematology articles for Stanford University, United States of America (USA)

Time frame: 1 June 2025 - 30 May 2026

View topic

Count: 88

Article ‘Count’ for Cardiovascular Medicine and Haematology.

Journal Count Share
1 0.06
Neighborhood-level socioeconomic position and mortality among children born with critical congenital heart defects 0.06
4 1.22
Molecular endotypes predict differential response to immunosuppressant therapy in non–idiopathic pulmonary fibrosis interstitial lung disease 0.27
CES1 Deficiency is Associated With Metabolic Reprograming and Endothelial Dysfunction in Pulmonary Arterial Hypertension 0.76
Hemodynamics and Phosphodiesterase-5 Inhibitor Treatment Associated with Survival in ILD-PH: A PVRI GoDeep Meta-Registry Analysis. 0.05
Proteomic Biomarkers of Survival in Non–Idiopathic Pulmonary Fibrosis Interstitial Lung Disease 0.14
1 0.06
Transfusion of Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in Cardiac Surgery - A Randomized Phase III Clinical Trial 0.06
1 1.00
Opportunistic Screening for Atrial Fibrillation With Continuous ECG Monitoring in the Emergency Department 1.00
1 0.00
Modeling the HLH immune synapse uncovers critical roles for IS termination, cytokine intensity, and target cell death 0.00
1 0.57
Artificial Intelligence-Based Echocardiography in Pulmonary Arterial Hypertension 0.57
9 1.90
The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. 0.06
The Fontan Outcomes Network: Findings After 2 Years and 1121 Participants. 0.03
Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. 0.05
Cardiac Allograft Vasculopathy Inhibition with Alirocumab: The CAVIAR Trial. 0.78
Deep Learning–Based Continuous QT Monitoring to Identify High-Risk Prolongation Events After Class III Antiarrhythmic Initiation 0.83
Health Status Outcomes With Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting in ISCHEMIA 0.08
Prognostic Role of Myocarditis-Like Episodes and Their Treatment in Patients With Pathogenic Desmoplakin Variants. 0.03
Human Single-Nucleus RNA Sequencing Identifies CD47 as a Therapeutic Target for Doxorubicin-Induced Cardiomyopathy. 0.01
The Impact of Fontan Circulatory Failure on Heart Transplant Survival: A 20-Center Retrospective Cohort Study. 0.04
1 0.10
Prognostic Value of Lung Injury Biomarkers in Patients Hospitalized With COVID-19 Without Respiratory Failure at Admission 0.10
5 1.18
Angina with non-obstructive coronary arteries and myocardial bridge: long-term outcomes of surgical unroofing 0.90
Osimertinib induces reversible cardiac dysfunction through the GATA4-MYLK3-MYL2 axis 0.05
Titin-related familial dilated cardiomyopathy: factors associated with disease onset 0.02
First myocardial infarction: risk factors, symptoms, and medical therapy 0.20
Immune checkpoint inhibitor-associated myocarditis: a novel risk score 0.02
1 0.07
Metformin and Time to Sustained Recovery in Adults With COVID-19 0.07
1 0.11
Z-Drug Use in the First Trimester of Pregnancy and Risk of Congenital Malformations 0.11
1 0.60
Temporal Trends of Common Cardiac Surgical Procedures at Veterans Affairs Medical Centers 0.60
5 0.20
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement 0.05
Metformin to Improve Walking Performance in Lower Extremity Peripheral Artery Disease 0.05
SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria 0.04
Effects of Sodium Glucose Cotransporter 2 Inhibitors by Diabetes Status and Level of Albuminuria 0.04
Impact of the MISSION Act on Quality and Outcomes of Major Cardiovascular Procedures Among Veterans 0.04
2 0.48
Therapeutic potential of synergistic mucociliary clearance for cystic fibrosis airways by combined 𝜷-adrenergic + cholinergic agonists 0.46
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma 0.02
2 0.29
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma. 0.06
Remission Assessment by Circulating Tumor DNA in Large B-cell Lymphoma. 0.23
6 3.32
Ten-year outcomes of valve-replacing versus valve-sparing aortic root replacement in Marfan syndrome patients: An observational multicenter study 0.08
Outcomes of Adults with Congenital Heart Disease Undergoing Heart and Heart-Liver Transplantation: A Single-Center Experience 1.00
Ex Vivo Heart Perfusion Offsets Ischemic Penalties with ≥6-Hour Preservation in Adult Donation-After-Brain-Death Heart Transplantation 1.00
Long-Term Outcomes for Patients Undergoing Hybrid Ablation for Atrial Fibrillation 0.92
Unplanned reinterventions after congenital cardiac surgery and hospital mortality: A report from the Pediatric Cardiac Critical Care Consortium (PC4) 0.10
Risk of Reoperation Following Rheumatic Mitral Repair: Long-term Longitudinal Analysis 0.22
12 1.72
Opportunistic Cardiovascular Risk Assessment Using Routine Head CT in the Emergency Department 0.22
Interchangeability of the KCCQ-12 and KCCQ-23 across gt;18,000 Participants Enrolled in 4 Large-Scale Trials of Heart Failure 0.08
Delayed Diagnosis of Transthyretin Amyloid Cardiomyopathy in the Veterans Health Administration 0.51
Using Artificial Intelligence to Adjudicate Major Adverse Cardiovascular Events in Clinical Trials 0.06
Trajectories of Angina After Initial Invasive vs Conservative Strategy for Chronic Coronary Disease 0.09
Left Ventricular Health and TAVR Timing in Asymptomatic Severe Aortic Stenosis: Analysis from the EARLY TAVR Trial 0.06
Artificial Intelligence Automation of Echocardiographic Measurements 0.36
Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR 0.04
Prevalence and Predictors of Neurocognitive Dysfunction in Adults With Congenital Heart Disease Results From MINDS-ACHD 0.05
Paclitaxel-Coated Balloon for the Treatment of Multilayer In-Stent Restenosis AGENT IDE Subgroup Analysis 0.04
Guideline-Directed Medical Therapy and Outcomes Among Patients With Heart Failure With Improved Ejection Fraction 0.16
Long-Term Survival and Patient-Reported Outcomes After Staged Reconstructive Surgery for Hypoplastic Left Heart Syndrome 0.04
1 0.07
Polygenic risk of coronary artery disease for long-term survivors of breast cancer 0.07
1 0.30
Comprehensive echocardiogram evaluation with view primed vision language AI 0.30
12 2.75
PDK4 drives abdominal aortic aneurysm by promoting smooth muscle cell metabolic reprogramming and NLRP3-mediated pyroptosis 0.05
Vascular smooth muscle cell state trajectories mediate molecular mechanisms of coronary disease risk 0.95
Expert-level probabilistic breathing event detector informs phenotyping of sleep apnea 0.33
Risk factors for mortality in patients with kidney failure on hemodialysis identified by proteomic analysis of CRIC and PACE studies 0.03
Functional genomics and tumor microenvironment analysis reveal prognostic biological subtypes in Mantle cell lymphoma 0.03
Genome-wide analysis of heart failure yields insights into disease heterogeneity and enables prognostic prediction in the Japanese population 0.02
Hypertrophic cardiomyopathy mutations Y115H and E497D disrupt the folded-back state of human β-cardiac myosin allosterically 0.57
Distinct cell state ecosystems for nodular lymphocyte-predominant Hodgkin lymphoma 0.59
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial 0.05
Integrated multiomics of pressure overload in the human heart prioritizes targets relevant to heart failure 0.03
Immature Acta2R179C/+ smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS 0.09
Association between self-reported multimorbidity and longitudinal brain Aβ deposition in Alzheimer’s disease 0.02
4 0.99
Zodasiran for cholesterol and triglyceride lowering in patients with hyperlipidemia: final report of phase 1 basket trial 0.13
Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial 0.02
Global, regional, and national burden of chronic respiratory diseases and impact of the COVID-19 pandemic, 1990–2023: a Global Burden of Disease study 0.00
Irradiation- and busulfan-free stem cell transplantation in Fanconi anemia using an anti-CD117 antibody: a phase 1b trial 0.84
3 1.39
Electrical stimulation promotes longevity and regeneration in a colonial chordate 0.64
TRIM21enhances IL-17A signaling and drives autoimmune myocarditis by promoting TRAF3 lysosomaldegradation in cardiac fibroblasts 0.08
A FRET assay to monitor different structural states of human β-cardiac myosin including the interacting-heads motif 0.67
1 0.05
Targeting modulated vascular smooth muscle cells in atherosclerosis via FAP-directed immunotherapy 0.05
1 0.92
Inhibition of CXCL10 and IFN-γ ameliorates myocarditis in preclinical models of SARS-CoV-2 mRNA vaccination 0.92
1 0.04
Impact of shifting blood donation policy from gift to honour model: staggered difference-in-differences analysis in China 0.04
2 0.25
Early life peanut oral immunotherapy associated with long-term ingestion and immunologic changes 0.20
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years 0.05
2 0.07
Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial 0.03
Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials 0.03
1 0.13
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial 0.13
1 0.19
Prevalence of non-communicable disease risk factors and chronic conditions among middle-aged and older adults in extreme poverty: a nationally representative cross-sectional study in India 0.19
2 0.07
Angiography-Derived Fractional Flow Reserve to Guide PCI 0.05
Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy 0.02
2 0.94
Loop gain predicts residual sleep apnoea among people using positive airway pressure 0.08
Randomised, placebo-controlled trial of oral hymecromone in adults with pulmonary hypertension 0.86

Numerical information only (in the tables above) is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International.